Liver Autoantibodies in Patients with Scleroderma PDF Print E-mail
Tuesday, 19 October 2010 20:53
Thelma L. Skare & Renato M. Nisihara & Osvaldo Haider & Pedro M. Azevedo & Shirley R. R. Utiyama
Received: 5 January 2010 / Revised: 13 August 2010 / Accepted: 26 September 2010
# Clinical Rheumatology 2010

Association between autoimmune liver diseases and scleroderma has been described. The purpose of this study was to study the prevalence of antimithocondrial antibody (AMA), antismooth muscle antibodies (SMA), and liverkidney-microsomal (LKM-1) autoantibody in a cohort of 63 scleroderma patients and 100 healthy controls. The autoantibodies AMA, SMA, and LKM were determined by indirect immunofluorescence. Patients' charts were reviewed for demographic data, scleroderma form, and clinical and antinuclear antibody profile, aiming a comparison between patients with and without liver autoantibodies. Nine patients (14.3%) were positive for at least one of the liver autoantibodies; only one patient had both AMA and SMA positive.

Antibody SMA was positive in 6.4% (4/63) patients; AMA was present in 9.52% (6/63) of them; none were positive to LKM-1. In the control group just one patient (1%) was SMA positive; the other autoantibodies were negative. There is an increased prevalence of liver autoantibodies in patients with scleroderma than in control population. These patients should be carefully followed for liver dysfunction.

Login to download your own copy of the full and original article from the link provided below

 
More articles :

» Scleroderma Research Foundation To Host Patient Webinar Series

The announced the first in a series of free informational Webinars for people living with and others directly or indirectly affected by the disease. The first Webinar will highlight new clinical trials and results from recent studies.The 2011/2012...

» The registry of the German Network for Systemic Scleroderma

N. Hunzelmann, E. Genth, T. Krieg, W. Lehmacher, I. Melchers, M. Meurer, P. Moinzadeh, U. Mu¨ ller-Ladner, C. Pfeiffer, G. Riemekasten, E. Schulze-Lohoff, C. Sunderkoetter, M. Weber, M. Worm, P. Klaus, A. Rubbert, K. Steinbrink, B. Grundt, R. Hein,...

» The SCOT Study

SCOT is a clinical research study designed for people with severe forms of . SCOT stands for Scleroderma: Cyclophosphamide Or Transplantation. The SCOT study will compare the potential benefits of stem cell transplant and high-dose monthly...

» Lidocaine for Systemic Sclerosis: A Double-blind Randomized Clinical Trial

Systemic sclerosis (scleroderma; SSc) is an orphan disease with the highest case-specific mortality of any connective-tissue disease. Excessive deposit in affected tissues is a key for the disease's pathogenesis and comprises most of the clinical...

» Skin Autofluorescence Is Not Increased in Patients with Systemic Sclerosis

M. E. Hettema, H. Bootsma, R. Graaff, R. de Vries, C. G. M. Kallenberg, and A. J. SmitReceived 24 May 2011; Accepted 8 August 2011Vascular involvement is a key factor in major manifestations of systemic sclerosis (SSc), such as Raynaud’s...

» New Research Finds Pattern For Detecting 'False-positive' ANA Results

The presence of antinuclear antibodies (ANA) indicates the possibility of and the indirect immunofluorescence (IIF) assay on HEp-2 cells is the standard blood test (ANA-HEp-2) used to detect ANA. However, studies have shown that a "false-positive"...